Bachrodt Amy 4

4 · Maze Therapeutics, Inc. · Filed Jan 26, 2026

AI-generated summary of this filing

Updated Jan 26, 2026

Maze Therapeutics (MAZE) SVP Amy Bachrodt Exercises Options, Sells Shares

What Happened

Amy Bachrodt, SVP Finance at Maze Therapeutics, exercised 5,000 stock options on Jan 22, 2026 (2,497 and 2,503 shares) at an exercise price of $10.42/share, costing $52,100 in total. On the same day she sold 5,000 common shares in the open market at a weighted average price of $45.52/share, generating proceeds of $227,612. The filing also shows two derivative "Disposed" entries at $0.00 related to the exercised options (reported as derivative dispositions).

Key Details

Transaction date: January 22, 2026.
Exercise: 5,000 options exercised at $10.42 each (total cost $52,100).
Sale: 5,000 shares sold, weighted avg price $45.52; total proceeds $227,612. Reported sale price range $45.00–$45.93 (multiple transactions).
Footnotes: Sale effected under a Rule 10b5-1 trading plan adopted Sept 29, 2025 (F1). Vesting schedules for the options are monthly (first tranches Apr 1, 2021 and Mar 1, 2022 per F3/F4). Weighted-average sale price detailed in F2.
Shares owned after transaction: not specified in this filing.
Filing timeliness: filed Jan 26, 2026 for a Jan 22, 2026 transaction (filed within required reporting window).

Context

This sequence—exercising options and selling the resulting shares the same day—is commonly a way for insiders to monetize vested options. The $0.00 derivative dispositions reported alongside the exercise are typical reporting entries when shares are netted or withheld in connection with option exercises; here the open‑market sale of 5,000 shares produced the cash proceeds shown. The 10b5-1 plan note indicates the sales were prearranged and scheduled.

Form 4

Period: 2026-01-22

SVP, Finance

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-01-22$10.42/sh+2,497$26,019→ 15,462 total
Exercise/Conversion
Common Stock
[F1]
2026-01-22$10.42/sh+2,503$26,081→ 17,965 total
Sale
Common Stock
[F1][F2]
2026-01-22$45.52/sh−5,000$227,612→ 12,965 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F3]
2026-01-22−2,497→ 486 total
Exercise: $10.42Exp: 2031-03-03→ Common Stock (2,497 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]
2026-01-22−2,503→ 7,869 total
Exercise: $10.42Exp: 2032-02-17→ Common Stock (2,503 underlying)

Footnotes (4)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.93 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
[F3]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2021, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
[F4]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on March 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Signature

/s/ Courtney Phillips, as attorney-in-fact|2026-01-26

1 file